Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
International AIDS Vaccine Initiative
Age
18–49
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
Has understood the information provided and has provided written informed consent before any study-related procedures are performed
Willing to undergo HIV testing, STI screening, HIV counselling and receive HIV and STI test results
At risk for HIV infection as defined by at least one of the following:
* Current sexually-transmitted infection (STI) or STI in the previous 3 months
* In the past 3 months had multiple episodes of unprotected vaginal sex
* In the past 3 months had multiple episodes of unprotected anal sex
* In the past 3 months engaged in sex work for money or drugs
If a female of childbearing potential (i.e., not post-menopausal or surgically sterile), using an effective method of non-barrier contraception (hormonal contraceptive; intrauterine device (IUD); surgical sterility) from 7 days prior to randomization until the end of the study. All female volunteers must be willing to undergo urine pregnancy tests
You may not be if
Confirmed HIV-1 or HIV-2 infection
Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator would make the volunteer unsuitable for the study, including severe infections requiring treatment such as tuberculosis, and alcohol or drug abuse
Any of the following abnormal laboratory parameters:
* Haemoglobin \<9.0 g/dL
* Creatinine clearance \<80mL/min, as calculated by Cockcroft-Gault equation
* AST: \>2.5 x ULN
* ALT: \>2.5 x ULN
* Total bilirubin \>1.5 x ULN
* Serum amylase \>1.5 x ULN
* Serum phosphorus \<2.4 mg/dL
* Urinalysis: Two abnormal dipsticks showing any of the following:
* blood = 2+ or more (not due to menses)
* protein = 1+ or more
* leucocytes = 2+ or more
* glucose= 1+ or more
Confirmed diagnosis of chronic hepatitis B infection (HBsAg positive)
If female, pregnant or planning a pregnancy within 4 months after enrolment or lactating
Participation in another clinical study of an investigational product currently, within the 3 months prior to enrolment or expected participation during this study
Clareo Health | A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa
